Wei Li

机构：Harbin Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Chongqing Medical University · ORCID：0000-0003-2283-0091

发表论文 75 篇 · 总被引 994 次 · h-index 18

代表论文

• Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial (2024 · Nature Communications · 被引 32)
• (8-Hydroxyquinoline) Gallium(III) Complex with High Antineoplastic Efficacy for Treating Colon Cancer via Multiple Mechanisms (2023 · ACS Omega · 被引 22)
• Development and characterization of an amorphous curcumin-Eudragit ® E100 solid dispersions with improved solubility, stability, and pharmacokinetic properties (2022 · Pharmaceutical Development and Technology · 被引 18)
• Quantitative Flow Ratio-Derived Index of Microcirculatory Resistance as a Novel Tool to Identify Microcirculatory Function in Patients with Ischemia and No Obstructive Coronary Artery Disease (2023 · Cardiology · 被引 12)
• Ultrasound and clinicopathological characteristics-based model for prediction of pathologic response to neoadjuvant chemotherapy in HER2-positive breast cancer: a case–control study (2023 · Breast Cancer Research and Treatment · 被引 10)
• The role of locoregional surgery in de novo stage IV breast cancer: A meta-analysis of randomized controlled trials (2024 · Cancer Treatment Reviews · 被引 8)